Medtronic (NYSE: MDT) up 1% before marketing in light volume in response to its announcement of positive preliminary results of the SPYRAL HTN-ON MED study evaluating its renal denervation system (RDN ) Symplicity Spyral in patients with high blood pressure who receive antihypertensive medications. The data were presented at EuroPCR in Paris and published in The Lancet .
In month 6, patients who received treatment with Symplicity Spyral experienced an average mean systolic reduction of 24 hours (blood pressure during heart contraction) ambulatory blood pressure (ABPM) of 9 mm Hg, 7.4 mm Hg greater than the simulated control (p = 0.005). The reduction in diastolic blood pressure (blood pressure between heartbeats) was 6.0 mm Hg, 4.1 mm Hg greater than the sham control (p = 0.029).
The positive results represent a victory for the company. A previous study, SYMPLICITY HTN-3, did not achieve the primary endpoint.
Renal denervation is a minimally invasive procedure based on a catheter that regulates the overactivity of the nerves leading to and from the kidney, which helps reduce blood pressure in patients inadequately controlled with medication.